Gilead Sciences Tech Radar: Acquiring in vivo cell therapy platforms to reduce costs

The single biggest technology story at Gilead Sciences is its aggressive investment in next-generation in vivo cell therapy platforms to reduce manufacturing costs and expand global access.

Executives confirmed the acquisition of Interius BioTherapeutics to secure a novel "viral vector" in vivo platform.

This off-the-shelf technology stimulates the patient's body to produce its own CAR-T cells, which executives note brings "simplified and cost-effective manufacturing processes" to drive cost optimization and rapid revenue growth.

Furthermore, Gilead is engineering next-generation "bicistronic" CD19/CD20 cell constructs designed to significantly improve safety profiles, which is a technology shift aimed at enabling lucrative revenue expansion into community outpatient settings and new autoimmune disease indications.

Gilead is also undergoing major commercial transformations requiring significant backend technology support.

The complex rollout of Yeztugo—a twice-yearly HIV prevention injectable—demands precise coordination of "white bagging" logistics with specialty pharmacies, buy-and-bill clinic integrations, and proactive digital patient reminders for re-dosing.

Executing these shifting logistical models and supporting a newly launched, broad direct-to-consumer (DTC) campaign logically requires the company to deploy and integrate sophisticated supply chain management tracking, CRM platforms, and data analytics systems.

All sourced directly from Gilead Sciences' Q4 2025 earnings call and recent investor conferences.